

Supplemental Information

SUPPLEMENTAL TABLE 4 GA and Birth Weight Among Infants Exposed to ADHD Medication (All Substances) During Pregnancy

| Outcome | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy | | |
|----------|---|---|---|
| | Factors Adjusted for in the Final Model | Factors Adjusted for in the Final Model | |
| GA, wk | <32 | Primiparity, opioids (N02A), antiepileptics (N03A), psycholeptics (N05) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | 32–36 | Opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | 37–41 | Reference | Reference |
| | ≥42 | Age, primiparity, maternal smoking, BMI, opioids (N02A), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Birth wt | SGA | Age, primiparity, maternal smoking, non-Nordic country of birth, psycholeptics (N05) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | AGA | Reference | Reference |
| | LGA | Age, primiparity, maternal smoking, BMI, non-Nordic country of birth, alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, antiepileptics (N03A), psycholeptics (N05), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |

Factors included in the final adjusted models of the logistic regression analyses. AGA, appropriate for gestational age; LGA; large for gestational age; SGA, small for gestational age.

SUPPLEMENTAL TABLE 5 Perinatal Morbidity Among Infants Exposed to ADHD Medication (All Substances) During Pregnancy

| Outcome | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy | ADHD Medication During Pregnancy Versus No ADHD Medication |
|--|---|---|
| | Factors Adjusted for in the Final Model | Factors Adjusted for in the Final Model |
| Apgar score <7 at 5 min | Year of childbirth, primiparity, BMI, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Birth defects (weeded) | Year of childbirth, age, primiparity, BMI, non-Nordic country of birth, antiepileptics (N03A), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Perinatal death | Non-Nordic country of birth, antiepileptics (N03A) | Age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| NICU admission | Age, primiparity, maternal smoking, BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Any respiratory disorder | Age, primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, primiparity, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Transient tachypnea or other respiratory disease | Age, maternal smoking, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01) and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| PPHN | Primiparity, alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, BMI, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| RDS | Year of childbirth, opioids (N02A) | Age, primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| CPAP | Primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Ventilator treatment | Maternal smoking, BMI, non-Nordic country of birth, psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Hyperbilirubinemia | Primiparity, BMI, opioids (N02A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, opioids (N02A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Hypoglycemia | Year of childbirth, age, primiparity, BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Feeding difficulties | Year of childbirth, primiparity, BMI, psycholeptics (N05), opioids (N02A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| CNS-related disorders | Psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Withdrawal symptoms to therapeutic drugs | BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, maternal smoking, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |

Factors included in the final adjusted models of the logistic regression analyses.

SUPPLEMENTAL TABLE 6 GA and Birth Weight Among Infants Exposed to ADHD Medication (Stimulant Substances Only) During Pregnancy

| Outcome | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy | ADHD Medication During Pregnancy Versus No ADHD Medication | |
|----------|---|---|---|
| | Factors Adjusted for in the Final Model | Factors Adjusted for in the Final Model | |
| GA, wk | <32 | Primiparity, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | 32–36 | Not living with father of child, opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | 37–41 | Reference | Reference |
| | ≥42 | Age, primiparity, maternal smoking, BMI, opioids (N02A), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Birth wt | SGA | Age, primiparity, maternal smoking, non-Nordic country of birth, psycholeptics (N05) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| | AGA | Reference | Reference |
| | LGA | Age, primiparity, maternal smoking, BMI, non-Nordic country of birth, alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, antiepileptics (N03A), psycholeptics (N05), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |

Factors included in the final adjusted models of the logistic regression analyses. AGA, appropriate for gestational age; LGA, large for gestational age; SGA, small for gestational age.

SUPPLEMENTAL TABLE 7 Perinatal Morbidity Among Infants Exposed to ADHD Medication (Stimulant Substances Only) During Pregnancy

| Outcome | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy | ADHD Medication During Pregnancy Versus No ADHD Medication |
|--|--|---|
| | Factors Adjusted for in the Final Model | Factors Adjusted for in the Final Model |
| Apgar score <7 at 5 min | Year of childbirth, primiparity, BMI, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Birth defects (weeded) | Year of childbirth, age, primiparity, BMI, non-Nordic country of birth, antiepileptics (N03A), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Perinatal death | Non-Nordic country of birth, antiepileptics (N03A) | Age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| NICU admission | Age, primiparity, maternal smoking, BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Any respiratory disorder | Age, primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, primiparity, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Transient tachypnea or other respiratory disease | Age, maternal smoking, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| PPHN | Primiparity, alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) | Year of childbirth, age, primiparity, BMI, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| RDS | Year of childbirth, opioids (N02A) | Age, primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| CPAP | Primiparity, maternal smoking, BMI, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Ventilator treatment | Maternal smoking, BMI, non-Nordic country of birth, psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |
| Hyperbilirubinemia | Primiparity, BMI, opioids (N02A), psycholeptics (N05) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, opioids (N02A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Hypoglycemia | Year of child birth, age, primiparity, BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| Feeding difficulties | Primiparity, BMI, psycholeptics (N05), opioids (N02A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, psycholeptics (N05), antidepressants (N06A), opioids (N02A), antiepileptics (N03A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |
| CNS-related disorders | Non-Nordic country of birth, psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, primiparity, maternal smoking, BMI, non-Nordic country of birth, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A) |

TABLE 7 Continued

| Outcome | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy | ADHD Medication During Pregnancy Versus No ADHD Medication |
|--|---|--|
| | Factors Adjusted for in the Final Model | Factors Adjusted for in the Final Model |
| Withdrawal symptoms to therapeutic drugs | BMI, opioids (N02A), psycholeptics (N05), antidepressants (N06A) | Year of childbirth, age, maternal smoking, not living with father of child, opioids (N02A), antiepileptics (N03A), psycholeptics (N05), antidepressants (N06A), alimemazine (R06AD01), and promethazine (R06AD02, R06AD52) |

Factors included in the final adjusted models of the logistic regression analyses.

SUPPLEMENTAL TABLE 8 Background Characteristics of Women Using ADHD Medication Before or After Pregnancy, Respectively

| Characteristic | ADHD Medication Before but Not During Pregnancy, ^a N = 3052 | ADHD Medication After but Not Before or During Pregnancy, ^b N = 6423 |
|------------------------------------|--|---|
| | % | % |
| Year of child birth | | |
| 2006–2010 | 19.3 | 80.0 |
| 2011–2014 | 80.7 | 20.0 |
| Maternal age, y | | |
| <20 | 11.3 | 6.1 |
| 35+ | 11.2 | 14.7 |
| Parity | | |
| Primipara | 76.3 | 48.4 |
| Multipara | 23.7 | 51.6 |
| BMI | | |
| BMI <18.5 | 2.9 | 2.4 |
| BMI >30 | 15.7 | 16.4 |
| Missing information | 8.1 | 9.7 |
| Maternal smoking | | |
| Yes | 25.8 | 26.7 |
| Missing information | 4.5 | 4.7 |
| Maternal country of birth | | |
| Sweden | 91.8 | 91.8 |
| Other Nordic | 1.1 | 1.6 |
| Non-Nordic | 6.7 | 6.6 |
| Not living with father of child | 23.1 | 18.7 |
| Maternal disease | | |
| Diabetes | 0.9 | 1.1 |
| Gestational diabetes | 1.0 | 1.0 |
| Hypothyroidism | 2.7 | 1.9 |
| Essential hypertension | 0.2 | 0.5 |
| Severe preeclampsia | 0.9 | 0.9 |
| Crohn's disease | 0.2 | 0.3 |
| Cesarean delivery | 19.9 | 20.7 |
| Use of other neurotropic drugs | | |
| Opioids (N02A) | 1.0 | 2.0 |
| Antiepileptics (N03A) ^c | 1.3 | 1.6 |
| Psycholeptics (N05) | 4.5 | 5.0 |
| Antidepressants (N06A) | 8.4 | 13.0 |
| Alimemazine (R06AD01) | 0.4 | 0.3 |
| Promethazine (R06AD02, R06AD52) | 4.0 | 4.0 |

^a Any prescription during the study period until 1 mo before pregnancy.

^b Any prescription during the study period after delivery but not before or during pregnancy.

^c Pregabalin, a substance classified as an antiepileptic but mainly used for other indications like anxiety and neuropathic pain, has previously been shown to be prescribed frequently to women with ADHD medication.³¹

SUPPLEMENTAL TABLE 9 GA and Birth Weight Among Infants Exposed to ADHD Medication (Stimulant Drugs Only) During Pregnancy, Compared With Infants Whose Mothers Used Any ADHD Medication Before or After Pregnancy, and to Infants Whose Mothers Never Used These Drugs

| Outcome | ADHD Medication During Pregnancy, ^a N = 1464 | | ADHD Medication Before or After Pregnancy, ^b N = 9475 | | No ADHD Medication, N = 953 688 | | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy ^c | | ADHD Medication During Pregnancy Versus No ADHD Medication ^c | |
|-----------------------|--|-------------|---|-----------------|------------------------------------|-----------------|---|--------------|--|--|
| | n (%) | n (%) | n (%) | n (%) | Crude OR (95% CI) | aOR (95% CI) | Crude OR (95% CI) | aOR (95% CI) | | |
| GA, wk | | | | | | | | | | |
| <32 | 17 (1.2) | 121 (1.3) | 12435 (1.3) | 0.9 (0.6–1.6) | 0.9 (0.6–1.5) | 0.9 (0.6–1.4) | | | | |
| 32–36 | 113 (7.7) | 561 (5.9) | 39 747 (4.2) | 1.3 (1.1–1.6) | 1.1 (0.9–1.4) | 1.3 (1.0–1.5)* | | | | |
| 37–41 | 1257 (85.9) | 8283 (87.4) | 838 318 (87.9) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | | | | |
| ≥42 | 77 (5.3) | 510 (5.4) | 63 168 (6.6) | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) | 0.9 (0.8–1.2) | | | | |
| Birth wt ^d | | | | | | | | | | |
| SGA | 38 (2.6) | 222 (2.3) | 21 789 (2.3) | 1.1 (0.8–1.6) | 1.1 (0.8–1.6) | 0.8 (0.6–1.2) | | | | |
| AGA | 1355 (92.6) | 8831 (93.2) | 892 606 (93.6) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | | | | |
| LGA | 71 (4.8) | 422 (4.5) | 39 273 (4.1) | 1.1 (0.9–1.4) | 1.2 (0.9–1.5) | 1.3 (1.0–1.6)* | | | | |

AGA, appropriate for gestational age; LGA, large for gestational age; ns, nonsignificant; SGA, small for gestational age.

^a Exposure to ADHD medication (stimulant substances) according to self-reported use in early pregnancy or any prescription during pregnancy or 1 mo before.

^b Any ADHD medication dispensed from a pharmacy during the study period except during the interval 1 mo before pregnancy until delivery.

^c The factors considered to be potential confounders were as follows: year of birth, maternal age, primiparity, BMI, maternal smoking, noncohabiting with father, mother born outside the Nordic countries, and maternal use of opioids, antiepileptics, psycholeptics, antidepressants, alimemazine, or promethazine during pregnancy. All were simultaneously entered into the introductory multiple logistic regression analyses. The final aORs were obtained from a restricted model after elimination of all variables with $P \geq .2$. A detailed list of the factors included in the final models is available in Supplemental Table 6.

^d Sex-specific birth wt z score; SGA = 2 SDs below mean, LGA = 2 SDs above mean.

* $P < .05$.

SUPPLEMENTAL TABLE 10 Perinatal Morbidity Among Infants Exposed to ADHD Medication (Stimulant Substances Only) During Pregnancy Compared With Infants Whose Mothers Used ADHD Medication Before or After Pregnancy and With Infants Whose Mothers Never Used These Drugs

| Outcome | ADHD Medication During Pregnancy, ^a N = 1464 | | ADHD Medication Before or After Pregnancy, ^b N = 9475 | | No ADHD Medication, N = 953668 | | ADHD Medication During Pregnancy Versus ADHD Medication Before or After Pregnancy ^c | | ADHD Medication During Pregnancy Versus No ADHD Medication ^c | |
|---|--|-------------|--|---------------|-----------------------------------|--------------------|---|--------------------|--|--|
| | n (%) | n (%) | n (%) | n (%) | n (%) | Crude OR (95% CI) | aOR (95% CI) | Crude OR (95% CI) | aOR (95% CI) | |
| Apgar score <7 at 5 min | 33 (2.3) | 177 (1.9) | 12592 (1.3) | 1.2 (0.8–1.7) | 1.0 (0.7–1.4) | 1.7 (1.2–2.4) | 1.1 (0.8–1.6) | 1.7 (1.2–2.4) | 1.1 (0.8–1.6) | |
| Birth defects (weeded) ^d | 42 (2.9) | 205 (2.2) | 20736 (2.2) | 1.3 (0.9–1.8) | 1.2 (0.8–1.7) | 1.3 (1.0–1.8 [ns]) | 1.2 (0.9–1.6) | 1.3 (1.0–1.8 [ns]) | 1.2 (0.9–1.6) | |
| Perinatal death | 8 (0.5) | 38 (0.4) | 4268 (0.4) | 1.4 (0.6–2.3) | 1.3 (0.6–2.8) | 1.2 (0.6–2.5) | 1.0 (0.5–1.9) | 1.2 (0.6–2.5) | 1.0 (0.5–1.9) | |
| NICU admission | 239 (16.3) | 1105 (11.7) | 79530 (8.3) | 1.5 (1.3–1.7) | 1.2 (1.1–1.5) | 2.1 (1.9–2.5) | 1.5 (1.3–1.7) | 2.1 (1.9–2.5) | 1.5 (1.3–1.7) | |
| Any respiratory disorder | 81 (5.5) | 511 (5.4) | 35479 (3.7) | 1.0 (0.8–1.3) | 0.9 (0.7–1.1) | 1.5 (1.2–1.90) | 0.9 (0.7–1.2) | 1.5 (1.2–1.90) | 0.9 (0.7–1.2) | |
| Transient tachypnea or other respiratory disease | 63 (4.3) | 346 (3.7) | 25198 (2.6) | 1.2 (0.9–1.5) | 1.0 (0.8–1.3) | 1.7 (1.3–2.1) | 1.1 (0.8–1.4) | 1.7 (1.3–2.1) | 1.1 (0.8–1.4) | |
| PPHN | 7 (0.5) | 49 (0.5) | 3065 (0.3) | 0.9 (0.4–2.9) | 0.9 (0.4–2.0) | 1.5 (0.7–3.1) | 1.0 (0.5–2.1) | 1.5 (0.7–3.1) | 1.0 (0.5–2.1) | |
| RDS | 12 (0.8) | 82 (0.9) | 5101 (0.5) | 0.9 (0.5–1.7) | 1.1 (0.6–2.9) | 1.5 (0.9–2.7) | 1.0 (0.6–1.8) | 1.5 (0.9–2.7) | 1.0 (0.6–1.8) | |
| CPAP | 54 (3.7) | 332 (3.5) | 22287 (2.3) | 1.1 (0.8–1.4) | 0.9 (0.7–1.2) | 1.6 (1.2–2.1) | 1.0 (0.7–1.3) | 1.6 (1.2–2.1) | 1.0 (0.7–1.3) | |
| Ventilator treatment | 12 (0.8) | 90 (0.9) | 5257 (0.6) | 0.8 (0.5–1.5) | 0.8 (0.4–1.5) | 1.5 (0.8–2.6) | 1.1 (0.6–1.9) | 1.5 (0.8–2.6) | 1.1 (0.6–1.9) | |
| Hyperbilirubinemia | 80 (5.5) | 511 (5.4) | 42948 (4.5) | 1.0 (0.8–1.3) | 1.0 (0.7–1.2) | 1.2 (1.0–1.5 [ns]) | 1.1 (0.9–1.3) | 1.2 (1.0–1.5 [ns]) | 1.1 (0.9–1.3) | |
| Hypoglycemia | 59 (4.0) | 326 (3.4) | 23965 (2.5) | 1.2 (0.9–1.6) | 0.9 (0.7–1.3) | 1.6 (1.3–2.1) | 1.1 (0.9–1.5) | 1.6 (1.3–2.1) | 1.1 (0.9–1.5) | |
| Feeding difficulties | 33 (2.3) | 130 (1.4) | 9837 (1.0) | 1.7 (1.1–2.5) | 1.4 (1.0–2.1 [ns]) | 2.2 (1.6–3.1) | 1.4 (0.9–1.9) | 2.2 (1.6–3.1) | 1.4 (0.9–1.9) | |
| CNS-related disorders | 12 (0.8) | 40 (0.4) | 2885 (0.3) | 1.8 (0.9–3.4) | 1.3 (0.7–2.6) | 2.7 (1.5–4.8) | 1.5 (0.9–2.7) | 2.7 (1.5–4.8) | 1.5 (0.9–2.7) | |
| Withdrawal symptoms from therapeutic drugs | 6 (0.4) | 10 (0.1) | 124 (0.0) | 3.6 (1.3–9.7) | — | 31.0 (13.8–71.3) | 1.9 (0.8–4.5) | 31.0 (13.8–71.3) | 1.9 (0.8–4.5) | |

ns, nonsignificant; —, not analyzed because of low number of infants.

^a Exposure to ADHD medication (stimulant substances) according to self-reported use in early pregnancy or any prescription during pregnancy or 1 mo before.

^b Any ADHD medication (stimulant substances) dispensed from a pharmacy during the study period except during the interval 1 mo before pregnancy until delivery.

^c The factors considered to be potential confounders were as follows: year of birth, maternal age, primiparity, BMI, maternal smoking, noncohabiting with father, mother born outside the Nordic countries, and maternal use of opioids, antiepileptics, psycholeptics, antidepressants, alimemazine, or promethazine during pregnancy. All were simultaneously entered into the introductory multiple logistic regression analyses. The final aORs were obtained from a restricted model after elimination of all variables with $P \geq .2$. A detailed list of the factors included in the final models is available in Supplemental Table 7.

^d ICD-10 diagnoses beginning with Q, excluding the following minor conditions: preauricular appendix, patent ductus arteriosus in a preterm infant, single umbilical artery, tongue tie, undescended testicle, hip dislocation or subluxation, and nevus.